A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 4310-4316

  Wang, Xueqing ^a   Wang, Guoqing ^a   Hao, Yueyue ^a   Xu, Yinhong ^a   Zhang, Lihua ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Cytology; EGFR mutation; Immunohistochemistry; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

AGED; BIOPSY; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC USE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; PROCEDURES; SENSITIVITY AND SPECIFICITY;

AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CYTOLOGICAL TECHNIQUES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84906248830     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD and Zhang S. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012; 25: 347-369.
2. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F and Favaretto A. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010; 30: 5121-5128.
3. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T and Ono M. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010; 16: 3163-3170.
4. Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J and Kage M. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011; 74: 35-40.
5. Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, Kinoshita T, Takeda M, Nakagawa K, Takamori S, Kuwano M, Ono M and Kage M. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012; 7: 122-127.
6. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X and Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15: 3023-3028.
7. Brevet M, Arcila M and Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010; 12: 169-176.
8. Seo AN, Park TI, Jin Y, Sun PL, Kim H, Chang H and Chung JH. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer 2014; 83: 316-323.
9. Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, Tsai MF, Lee YC, Yu CJ and Shih JY. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2013; 6: e23303.
10. Zhao J, Wang X, Xue L, Xu N, Ye X, Zeng H, Lu S, Huang J, Akesu S, Xu C, He D, Tan Y, Hong Q, Wang Q, Zhu G, Hou Y and Zhang X. The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer. J Cancer Res Clin Oncol 2013; 140: 849-857.
11. Pao W and Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
12. Pao W and Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007; 13: 4954-4955.
13. Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y and Li T. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol 2013; 8: 27.
14. Fan XS, Liu B, Yu B, Shi SS, Wang X, Zhang J, Wang JD, Lu ZF, Ma HH and Zhou XJ. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of del E746-A750 and L858R in lung adenocarcinomas]. Zhonghua Bing Li Xue Za Zhi 2013; 42: 173-177.
15. Hasanovic A, Ang D, Moreira AL and Zakowski MF. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012; 77: 299-305.
16. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M and Speake G. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010; 29: 132.